TY - JOUR
T1 - Protein-based Nanoparticle Vaccine Approaches Against Infectious Diseases
AU - Tapia, Daniel
AU - Reyes-Sandoval, Arturo
AU - Sanchez-Villamil, Javier I.
N1 - Publisher Copyright:
© 2023 Instituto Mexicano del Seguro Social (IMSS)
PY - 2023/4
Y1 - 2023/4
N2 - The field of vaccine development has seen an increase in the number of rationally designed technologies that increase effectiveness against vaccine-resistant pathogens, while not compromising safety. Yet, there is still an urgent need to expand and further understand these platforms against complex pathogens that often evade protective responses. Nanoscale platforms have been at the center of new studies, especially in the wake of the coronavirus disease 2019 (COVID-19), with the aim of deploying safe and effective vaccines in a short time period. The intrinsic properties of protein-based nanoparticles, such as biocompatibility, flexible physicochemical characteristics, and variety have made them an attractive platform against different infectious disease agents. In the past decade, several studies have tested both lumazine synthase-, ferritin-, and albumin-based nanoplatforms against a wide range of complex pathogens in pre-clinical studies. Owed to their success in pre-clinical studies, several studies are undergoing human clinical trials or are near an initial phase. In this review we highlight the different protein-based platforms, mechanisms of synthesis, and effectiveness of these over the past decade. In addition, some challenges, and future directions to increase their effectiveness are also highlighted. Taken together, protein-based nanoscaffolds have proven to be an effective means to design rationally designed vaccines, especially against complex pathogens and emerging infectious diseases.
AB - The field of vaccine development has seen an increase in the number of rationally designed technologies that increase effectiveness against vaccine-resistant pathogens, while not compromising safety. Yet, there is still an urgent need to expand and further understand these platforms against complex pathogens that often evade protective responses. Nanoscale platforms have been at the center of new studies, especially in the wake of the coronavirus disease 2019 (COVID-19), with the aim of deploying safe and effective vaccines in a short time period. The intrinsic properties of protein-based nanoparticles, such as biocompatibility, flexible physicochemical characteristics, and variety have made them an attractive platform against different infectious disease agents. In the past decade, several studies have tested both lumazine synthase-, ferritin-, and albumin-based nanoplatforms against a wide range of complex pathogens in pre-clinical studies. Owed to their success in pre-clinical studies, several studies are undergoing human clinical trials or are near an initial phase. In this review we highlight the different protein-based platforms, mechanisms of synthesis, and effectiveness of these over the past decade. In addition, some challenges, and future directions to increase their effectiveness are also highlighted. Taken together, protein-based nanoscaffolds have proven to be an effective means to design rationally designed vaccines, especially against complex pathogens and emerging infectious diseases.
KW - Ferritin
KW - Infectious diseases
KW - Lumazine synthase
KW - Nanoparticles
KW - Serum albumin
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=85149624038&partnerID=8YFLogxK
U2 - 10.1016/j.arcmed.2023.02.003
DO - 10.1016/j.arcmed.2023.02.003
M3 - Artículo de revisión
C2 - 36894463
AN - SCOPUS:85149624038
SN - 0188-4409
VL - 54
SP - 168
EP - 175
JO - Archives of Medical Research
JF - Archives of Medical Research
IS - 3
ER -